Day’s Recap is unavailable for this topic and date. Feel free to go through our curated list of stories below.
Other Developments
A curated list of other prominent stories from this day.
5:27 PMBloomberg Markets
Shionogi-Backed Apnimed Files for IPO to Fund Sleep Apnea Drug
Summary
Apnimed filed for a US IPO to raise capital as its oral drug candidate for obstructive sleep apnea moves toward commercialization. The offering would fund late-stage development and prepare the company for a launch in a market dominated by device-based therapy.
Why it matters
A successful oral alternative could reshape treatment adherence and spending in one of the largest under-treated chronic respiratory conditions.
We mapped every UES cooling tower in the area affected by NYC’s latest Legionnaires’ outbreak
Summary
A map of Upper East Side cooling towers shows when each site was last inspected and when building owners last reported Legionella testing. The dataset is framed around the zone linked to New York City’s latest Legionnaires’ outbreak and flags gaps in timeliness across buildings.
Why it matters
Cooling tower oversight is one of the few levers the city has to prevent airborne Legionella spread, and the compliance trail can quickly determine where public health action and liability concentrate.
Bayer Sells $3.4 Billion Contraceptives Stake to Apollo
Summary
Bayer sold a minority stake in its contraceptives business to Apollo for €3 billion to raise cash. The proceeds will help fund costs tied to Roundup litigation.
Why it matters
When litigation drives asset sales, it changes how the market values the company’s remaining portfolio and its ability to fund legal resolutions without diluting shareholders.
This frog bacterium wiped out cancer tumors in mice with a single dose
Summary
Researchers report that a bacterium naturally found in amphibian intestines eliminated colorectal tumors in mice after a single treatment. The microbe appeared to both directly damage cancer cells and trigger an anti-tumor immune response, suggesting potential for broader solid-tumor therapy.
Why it matters
It points to a new therapeutic class that could make durable, immune-mediated tumor clearance possible with simpler dosing, if safety and translation barriers can be cleared.